Literature DB >> 14550584

Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element.

Hiromichi Dansako1, Atsushi Naganuma, Takashi Nakamura, Fusao Ikeda, Akito Nozaki, Nobuyuki Kato.   

Abstract

We previously found that hepatitis C virus (HCV) core protein, which possesses the consensus sequence of genotype 1b, transcriptionally activates the interferon (IFN)-inducible 2'-5'-oligoadenylate synthetase (2'-5'-OAS) gene in human hepatocyte cells. To clarify the mechanism of this activation, we further characterized the core protein as an activator of the 2'-5'-OAS gene. We demonstrated that the activation of the 2'-5'-OAS gene by the core protein is a general phenomenon, regardless of HCV genotype and strain. We showed that the 20 N-terminal amino acids (aa) of the core protein were important to the activation of the 2'-5'-OAS gene, although this N-terminal region did not have any effect on the subcellular localization of the core protein. We demonstrated that the core protein was able to activate all promoters possessing the IFN-stimulated response element (ISRE) examined. However, we found that the level of activation of the 2'-5'-OAS gene promoter possessing a particular variant type of ISRE was significantly higher than that of other IFN-inducible gene promoters. This phenomenon was confirmed using synthetic promoters possessing five repeats of the consensus or a 2'-5'-OAS-type ISRE. In addition, we showed that gene activation induced by the core protein is mediated by the ISRE. These results imply that the core protein prefers a subclass of IFN-inducible genes, the promoters of which possess the 2'-5'-OAS-type ISRE. Accordingly, we found that the IFN-inducible double-stranded RNA-specific adenosine deaminase gene promoter, possessing a 2'-5'-OAS-type ISRE sequence, was also efficiently activated by the core protein. The exact mechanism by which the core protein enhances gene expression was not determined, but we could find no effects of core protein on gene expression and phosphorylation status of the components of the JAK-STAT signaling transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550584     DOI: 10.1016/s0168-1702(03)00218-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  Genotypic Regulation of Type I Interferon Induction Pathways by Frameshift (F) Proteins of Hepatitis C Virus.

Authors:  Yi-Ting Lai; Yih-Mei Liou; Fu Hsin; Helene Minyi Liu
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

2.  The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice.

Authors:  Wenbo Zhu; Yanzi Chang; Chunchen Wu; Qingxia Han; Rongjuan Pei; Mengji Lu; Xinwen Chen
Journal:  Clin Vaccine Immunol       Date:  2010-06-02

Review 3.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

4.  Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.

Authors:  Sabrina Marozin; Enrico N De Toni; Antonia Rizzani; Jennifer Altomonte; Alexandra Junger; Günter Schneider; Wolfgang E Thasler; Nobuyuki Kato; Roland M Schmid; Oliver Ebert
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

Review 5.  Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy.

Authors:  Daniela Ploen; Eberhard Hildt
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

6.  Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities.

Authors:  Weilin Gu; Youki Ueda; Hiromichi Dansako; Shinya Satoh; Nobuyuki Kato
Journal:  FASEB Bioadv       Date:  2021-03-04

7.  Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells.

Authors:  Hiromichi Dansako; Daisuke Yamane; Christoph Welsch; David R McGivern; Fengyu Hu; Nobuyuki Kato; Stanley M Lemon
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

8.  Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients.

Authors:  Michele Malaguarnera; Marco Vacante; Cristina Russo; Maria Pia Gargante; Maria Giordano; Gaetano Bertino; Sergio Neri; Mariano Malaguarnera; Fabio Galvano; Giovanni Li Volti
Journal:  Hepat Mon       Date:  2011-02       Impact factor: 0.660

Review 9.  Modulation of host metabolism as a target of new antivirals.

Authors:  Masanori Ikeda; Nobuyuki Kato
Journal:  Adv Drug Deliv Rev       Date:  2007-08-11       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.